Angel Garcia
Internal Medicine · Coral Springs, FLNPI 1902969603
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GSK accounts for 82.2% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.
Across 2 payments — averaging $67.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$110
- AbbVie$24
Across 58 payments — averaging $18,372 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$754K
- Avanir Pharmaceuticals, Inc.$179K
- Currax Pharmaceuticals LLC$83K
- Biohaven Pharmaceutical Holding Company Ltd.$47K
- Amgen$2K
What the payments were for
- Food & beverage$134100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$110
How this compares
$134 in reported general payments places this provider in the 30th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 103 | $31,993 |
| AptiomEslicarbazepine Acetate | 16 | $11,077 |
| XareltoRivaroxaban | 32 | $9,442 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,677 |
| JanuviaSitagliptin Phosphate | 11 | $3,494 |
| Atorvastatin Calcium | 106 | $2,053 |
| Gabapentin | 51 | $1,513 |
| Potassium Chloride | 24 | $1,104 |
| AmantadineAmantadine Hcl | 22 | $1,031 |
| ClopidogrelClopidogrel Bisulfate | 75 | $997 |
| Levetiracetam | 19 | $942 |
| Pantoprazole Sodium | 61 | $932 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $813 |
| Baclofen | 25 | $757 |
| Levothyroxine Sodium | 32 | $708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $110 | $7,67711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Coral Springs
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.